3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
6
Active not recruiting
3
Terminated
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
57
Carcinoma, Non-Small-Cell Lung
29
Breast Neoplasms
18
Rectal Neoplasms
14
Ovarian Neoplasms
14
Carcinoma, Hepatocellular
10
Neoplasm Metastasis
9
Glioblastoma
9
Colonic Neoplasms
9
Carcinoma, Renal Cell
8
Uterine Cervical Neoplasms
7
Fallopian Tube Neoplasms
7
Brain Neoplasms
6
Neoplasms
5
Nasopharyngeal Carcinoma
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Liver Neoplasms
4
Inflammatory Breast Neoplasms
4
Colorectal Cancer Metastatic
4
Carcinoma, Ovarian Epithelial
4
Stomach Neoplasms
3
Pleural Effusion, Malignant
3
Meningeal Carcinomatosis
3
Melanoma
3
Kidney Neoplasms
3
Glioma
3
Non-squamous Non-small Cell Lung Cancer
2
Liver Metastasis Colon Cancer
2
Interventions
pembrolizumab
4
anlotinib
4
sintilimab
3
Paclitaxel
3
Leucovorin
3
Cetuximab
3
niraparib
2
Sorafenib
2
Radiotherapy
2
Nivolumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Docetaxel
2
Cisplatin
2
vistusertib
1
titanium silicide
1
tislelizumab
1
tirbanibulin
1
surufatinib
1
regorafenib
1
pemigatinib
1
olaparib
1
elemene
1
durvalumab
1
donafenib
1
daromun
1
avelumab
1
aumolertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma
×
Bevacizumab
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled